Embattled drug giant Valeant Pharmaceuticals (VRX) beat Q3 estimates and raised its guidance Monday, but the stock was down 5% in early trading as the CEO admitted that recent controversy over its prices is leading to new strategies, including a possible sale of its neurology business. Valeant said its cash EPS in the quarter totaled $2.74 a share, up 30% from the year-earlier quarter and beating analysts’ consensus by 4 cents, according to
Specialty-drug giant Valeant Pharmaceuticals (VRX) is set to report Q3 earnings Monday before the open, but the company’s emerging role as chief villain to drug-price critics is already overshadowing the report. On Wednesday, Valeant said that it had received subpoenas from district attorneys in Massachusetts and New York after members of both the House and Senate advocated looking into the enormous price increases that the company has given some
Valeant Pharmaceuticals (VRX) stock fell early Thursday after the drugmaker said late Wednesday that it had received a federal subpoena over its drug-pricing policy. Valeant said it received subpoenas from the U.S. District Attorneys of Massachusetts and southern New York, which “relate to documents with respect to our patient assistance programs, and also include requests relating to financial support provided by the company for patients,